Drugs / TAS-114
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02454062 | Mar 2013 → Dec 2016 | neoplasm | Taiho Oncology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02025803 | Nov 2012 → Jul 2017 | neoplasm | Taiho Oncology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01610479 | Jun 2012 → Feb 2017 | cancer | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02855125 Comparator | Aug 2016 → Sep 2017 | non-small cell lung carcinoma | Taiho Oncology, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-04-13 | Taiho Oncology, Inc. | Results Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compounds at the 109th Annual Meeting of the American Association for Cancer Research taihooncology.com ↗
The study found that TAS-114 combined with capecitabine (at 30% of its standard dose) achieved an equivalently efficacious 5-fluorouracil (5-FU) exposure as the standard capecitabine dose alone, with acceptable safety and preliminary efficacy in patients with advanced solid tumors. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-04-13 | Taiho Oncology, Inc. | Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compounds at the 109th Annual Meeting of the American Association for Cancer Research taihooncology.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02025803 ↗ |
| Action | Inhibit | “novel dUTPase inhibitor” PMID 30511200 ↗ Dec 2018 |
| Route | Oral | “TAS-114 and S-1 were concurrently administered orally under fasting conditions” PMID 30511200 ↗ Dec 2018 |